Champions Oncology Reports Record Annual Revenue of $59 Million
CHAMPIONS ONCOLOGY, INC. (CSBR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 csbr8-k4302026exhibit991.htm EX-99.1 Document Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Champions Oncology Reports Record Annual Revenue of $59 Million Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA Hackensack, NJ – July 27,
How this was made
The 30-second read
Why it matters
Traders can reassess CSBR’s run-rate profitability and margin profile based on record revenue, improved oncology services margin, and positive adjusted EBITDA across all quarters, while also weighing cash burn and the shift in revenue composition.
Market read
Record annual revenue and sustained positive adjusted EBITDA are the core new datapoints, alongside a higher Q4 oncology services margin and continued investment in radiopharmaceuticals and the data platform.
What to watch
The article attributes FY revenue growth partly to the absence of prior-year non-recurring data license revenue and notes temporary outsourced radiopharmacology costs; margin could compress as outsourcing changes.
Background
The company filed an SEC 8-K (Item 2.02) with Exhibit 99.1 reporting financial results for the fiscal year and fourth quarter ended April 30, 2026.
Ticker impact
Champions Oncology reported FY2026 revenue of $59.4M and positive adjusted EBITDA in each quarter, plus Q4 oncology services margin of 51%.
Near-term bias modestly positive, with traders focusing on margin durability and the shift away from non-recurring data license revenue.
This is a primary 8-K financial results disclosure with multiple concrete metrics (revenue, margin, adjusted EBITDA, cash/no debt). However, the excerpt is truncated before full guidance or outlook, limiting conviction on forward trajectory.
Market effects
Signals improving economics in oncology research services and radiopharmaceutical build-out, which can influence sentiment toward small-cap translational model providers.
Limited, company-specific impact likely confined to US small-cap biotech/research services sentiment.
Low; no international regulatory or cross-border deal details disclosed in the provided text.
Counterpoint
Adjusted EBITDA remains small ($1.6M FY), and operating cash flow was negative in the quarter, so the quality and sustainability of profitability may be fragile.
Key entities
- companyChampions Oncology, Inc.
Nasdaq-listed oncology research models and translational solutions provider reporting FY2026 and Q4 results.
- executiveRobert Brainin
CEO quoted on strategic progress including radiopharmaceutical platform expansion and progress toward commercial application of Corellia’s technology.
- executiveDavid Miller
CFO quoted on record revenue despite absence of prior-year data licensing transaction and disciplined cost management.